All terms in ADO

Label Id Description
eligibility criterion OBI_0500026 [an eligibility criterion (rule) is_a selection criterion which defines and states the requirements (positive or negative) for an entity to be considered as suitable for a given task or participation in a process. ]
positron emission tomography (PET) MMO_0000129 [Detection of gamma rays emitted from tissues after administration of natural biochemical substance into which positron emitting isotopes have been incorporated. The paths of the gamma rays resulting from collision of positrons and electrons are interpreted by a computer to form a representation of local concentrations of the isotope-containing substance.]
inclusion criterion OBI_0500027 [an inclusion criterion (rule) is_a *eligibility criterion* which defines and states a condition which, if met, makes an entity suitable for a given task or participation in a given process. For instance, in a study protocol, inclusion criteria indicate the conditions that prospective subjects MUST meet to be eligible for participation in a study.]
amnestic symptom ADO_0000064 [A symptom including impairment in learning and recalling of recently learned information, loss of memory, disorientation with time and space, lack of insight to their memory loss and being aware of their memory loss but not being able to understand why.]
insidious onset of dementia ADO_0000063 [A stage where symptoms have a gradual onset over months to years but with harmful effects, not sudden within hours or days.]
impaired language functions ADO_0000062 [A symptom including defficulty thinking of common words while speaking, hesitations, speech, spelling, and writing errors.]
impaired reasoning ADO_0000061 [A symptom with which a patient may misunderstand the motives of the actions of their family, friends or others]
asymptomatic cerebral amyloidosis ADO_0000068 [A biological process by which an individual has biomarker evidence of amyloid-beta accumulation with elevated tracer retention on PET amyloid imaging and/or low amyloid-beta 42 in CSF assay, but no detectable evidence of additional brain alterations suggestive of neurodegeneration or subtle cognitive and/or behavioral symptomatology.]
sudden onset of cognitive impairment ADO_0000067 [A stage where cognitive impiarment suddenly arises]
possible Alzheimer dementia ADO_0000066 [A type of Alzheimer dementia whic meets core clinical criteria for possible Alzheimer dementia]
dementia due to Alzheimer's disease ADO_0000050 [A disease of which the patient at this stage suffer from memory loss, impaired ability to think, or making decisions that interferes with doing everyday activities.]
non-demented cognitive impairment ADO_0000065 [A symptom that is sufficiently mild that there is no evidence of a significant impairment in social or occupational functioning.]
probable Alzheimer dementia ADO_0000059 [A type of dementia which which the person meets the core clinical creteria for probable Alzheimer dementia.]
longitudinal cognitive evaluation ADO_0000058 [A clinical tool that measures and evaluates cognition of the patient with certain time intervals while maintaining the consistency in parameters employed in testing.]
glutamine CHEBI_28300 [An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.]
GAPDH OGG_3000002597
PRNP OGG_3000005621
CNP OGG_3000001267
squalene CHEBI_15440 [A triterpene consisting of 2,6,10,15,19,23-hexamethyltetracosane having six double bonds at the 2-, 6-, 10-, 14-, 18- and 22-positions with (all-E)-configuration.]
episodic memory impairment ADO_0000053 [A mental impairment in the ability to learn and retain new information, or recall information about a specific event that has occurred at a specific time and place.]